Brokerages predict that Xenon Pharmaceuticals Inc (NASDAQ:XENE) will report earnings of ($0.49) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Xenon Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.61) and the highest is ($0.41). Xenon Pharmaceuticals reported earnings per share of ($0.33) during the same quarter last year, which suggests a negative year over year growth rate of 48.5%. The company is expected to issue its next earnings report on Tuesday, November 5th.

On average, analysts expect that Xenon Pharmaceuticals will report full-year earnings of ($1.88) per share for the current financial year, with EPS estimates ranging from ($2.18) to ($1.68). For the next fiscal year, analysts forecast that the firm will report earnings of ($1.92) per share, with EPS estimates ranging from ($2.39) to ($1.58). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that that provide coverage for Xenon Pharmaceuticals.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.46) by $0.09.

XENE has been the subject of several recent research reports. BidaskClub cut shares of Xenon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, June 11th. Zacks Investment Research raised shares of Xenon Pharmaceuticals from a “sell” rating to a “hold” rating and set a $11.00 price target for the company in a research report on Thursday, August 8th.

Several hedge funds and other institutional investors have recently made changes to their positions in XENE. Morgan Stanley increased its position in Xenon Pharmaceuticals by 25.3% during the second quarter. Morgan Stanley now owns 6,148 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 1,241 shares during the last quarter. Northern Trust Corp grew its holdings in Xenon Pharmaceuticals by 18.9% during the 4th quarter. Northern Trust Corp now owns 12,246 shares of the biopharmaceutical company’s stock valued at $77,000 after purchasing an additional 1,948 shares in the last quarter. Geode Capital Management LLC acquired a new stake in Xenon Pharmaceuticals during the 4th quarter valued at $88,000. Athanor Capital LP acquired a new stake in Xenon Pharmaceuticals during the 2nd quarter valued at $100,000. Finally, A.R.T. Advisors LLC acquired a new stake in Xenon Pharmaceuticals during the 2nd quarter valued at $106,000. 70.39% of the stock is currently owned by institutional investors.

Xenon Pharmaceuticals stock traded up $0.01 during trading on Thursday, hitting $8.88. The company had a trading volume of 350 shares, compared to its average volume of 43,783. Xenon Pharmaceuticals has a 1-year low of $5.41 and a 1-year high of $15.92. The company has a current ratio of 11.07, a quick ratio of 11.07 and a debt-to-equity ratio of 0.18. The company’s 50 day simple moving average is $9.64 and its 200-day simple moving average is $9.37. The stock has a market cap of $226.52 million, a price-to-earnings ratio of -6.61 and a beta of 1.33.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals, Inc engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P.

See Also: What are the benefits of a balanced fund?

Get a free copy of the Zacks research report on Xenon Pharmaceuticals (XENE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Xenon Pharmaceuticals (NASDAQ:XENE)

Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.